Neutralizing antibodies and the pathogenesis of HTLV-1: Insights from clinical cohorts | ||
| dc.conicet.organizacion | Universidad Nacional de Córdoba. Facultad de Medicina. Instituto de Virología Dr. J. M. Vanella | |
| dc.conicet.organizacion | Universidad Nacional de Córdoba. Facultad de Medicina. Instituto de Virología Dr. J. M. Vanella | |
| dc.conicet.organizacion | Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba | |
| dc.conicet.organizacion | Universidad Nacional de Córdoba. Facultad de Medicina. Instituto de Virología Dr. J. M. Vanella | |
| dc.conicet.organizacion | Universidad Nacional de Córdoba. Facultad de Ciencias Exactas, Físicas y Naturales | |
| dc.conicet.organizacion | Universidad Nacional de Córdoba. Facultad de Medicina. Instituto de Virología Dr. J. M. Vanella | |
| dc.contributor.author | Blanco, Sebastián | |
| dc.contributor.author | Lingua, Giuliana | |
| dc.contributor.author | Gomez, Lucia del Pilar | |
| dc.contributor.author | Mangeaud, A. | |
| dc.contributor.author | Gallego, Sandra Veronica | |
| dc.date.issued | 2025-11 | |
| dc.description.abstract | Recent advances in mRNA-based vaccines have generated renewed interest in strategies to prevent Human T-Lymphotropic Virus type 1 (HTLV-1) infection. To explore this, we evaluated neutralizing antibody (NtAb) responses in 47 HTLV-1–infected individuals from Northwestern Argentina, an endemic region with high intrafamilial transmission and frequent cases of HTLV-1–associated myelopathy/tropical spastic paraparesis (HAM/TSP). Using a syncytium-inhibition assay, we quantified NtAb titers across three groups: asymptomatic carriers (n = 17), oligosymptomatic individuals (n = 20), and HAM/TSP patients (n = 10). NtAb titers ranged from 1/50 to 1/4000, with more than half of the samples showing titers between 1/500 and 1/1000. No significant differences were observed between groups, nor correlations with neurological signs, suggesting that NtAb responses are not predictive biomarkers for HTLV-1 disease progression. Also, our results demonstrated that NtAb generated in vivo would not be protective for the development of TSP/HAM. These findings indicate that while neutralizing antibodies may prevent infection, they are unlikely to modify outcomes in infected individuals. Broader vaccine approaches targeting multiple HTLV-1 antigens may therefore be required to improve both prevention and clinical management. | es |
| dc.description.fil | Fil: Blanco, Sebastián. Universidad Nacional de Córdoba. Facultad de Medicina. Instituto de Virología Dr. J. M. Vanella; Argentina | |
| dc.description.fil | Fil: Lingua, Giuliana. Universidad Nacional de Córdoba. Facultad de Medicina. Instituto de Virología Dr. J. M. Vanella; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba; Argentina | |
| dc.description.fil | Fil: Gomez, Lucia del Pilar. Universidad Nacional de Córdoba. Facultad de Medicina. Instituto de Virología Dr. J. M. Vanella; Argentina | |
| dc.description.fil | Fil: Mangeaud, A.. Universidad Nacional de Córdoba. Facultad de Ciencias Exactas, Físicas y Naturales; Argentina | |
| dc.description.fil | Fil: Gallego, Sandra Veronica. Universidad Nacional de Córdoba. Facultad de Medicina. Instituto de Virología Dr. J. M. Vanella; Argentina | |
| dc.format | application/pdf | es |
| dc.identifier.citation | Blanco, Sebastián; Lingua, Giuliana; Gomez, Lucia del Pilar; Mangeaud, A.; Gallego, Sandra Veronica; Neutralizing antibodies and the pathogenesis of HTLV-1: Insights from clinical cohorts; Academic Press Ltd - Elsevier Science Ltd; Microbial Pathogenesis; 210; 11-2025 | es |
| dc.identifier.institucional | CONICET | |
| dc.identifier.issn | 0882-4010 | es |
| dc.identifier.repo | CONICET Digital | |
| dc.identifier.uri | http://hdl.handle.net/11336/280466 | |
| dc.journal.pais | Estados Unidos | es |
| dc.journal.title | Microbial Pathogenesis | es |
| dc.journal.volume | 210 | es |
| dc.language.iso | eng | es |
| dc.publisher | Academic Press Ltd - Elsevier Science Ltd | es |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/doi/https://doi.org/10.1016/j.micpath.2025.108190 | |
| dc.rights | info:eu-repo/semantics/restrictedAccess | * |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ | * |
| dc.subject | HTLV-1 | es |
| dc.subject | Neutralizing antibodies | es |
| dc.subject | Vaccine | es |
| dc.subject | HTLV pathogenesis | es |
| dc.subject.classification | Virología | es |
| dc.subject.classification | Ciencias Biológicas | es |
| dc.subject.classification | CIENCIAS NATURALES Y EXACTAS | es |
| dc.title | Neutralizing antibodies and the pathogenesis of HTLV-1: Insights from clinical cohorts | es |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:ar-repo/semantics/artículo | |
| dc.type | info:eu-repo/semantics/publishedVersion | |
Archivos
Bloque original
Cargando...
- Nombre:
- CONICET_Digital_Nro.dcb99c51-db1d-4aaf-8819-de2d1aea1e3d_B.pdf
- Tamaño:
- 324.82 KB
- Formato:
- Adobe Portable Document Format